Social welfare

The National Development and Reform Commission issued the"14th Five Year Plan"Bioeconomy Development Plan

Currently,cutting-edge research in the field of life sciences continues to be active,and the wave of biotechnology revolution has swept the world and accelerated its integration into economic and social development,providing new solutions for humanity to address major challenges such as life and health,climate change,resource and energy security,and food security.The Outline of the 14th Five Year Plan clearly proposes to promote the integration and innovation of biotechnology and information Technological convergence,accelerate the development of biomedicine,biological breeding,biomaterials,Bioenergy and other industries,and make the Bioeconomy bigger and stronger.In order to thoroughly implement the decisions and arrangements of the CPC Central Committee and the State Council,scientifically plan and systematically promote the high-quality development of Bioeconomy in China,the National Development and Reform Commission has issued the 14th Five Year Bioeconomy Development Plan(hereinafter referred to as the"Plan")with the approval of the State Council

Notice on Further Strengthening Drug Safety Management and Improving the Level of Reasonable Drug Use

Strengthen the implementation of medication safety systems.Medical institutions should improve and implement medication safety related systems,enhance the awareness and ability of medical and technical personnel to prevent medication errors,and implement the full process management of prescription issuance,dispensing,administration,and medication.Physicians should provide correct,standardized,and appropriate prescriptions based on the patient's condition;The pharmacist carefully performs the responsibility of prescription review,and all prescriptions and medication orders are dispensed after being reviewed as qualified;Nurses and other medical personnel who execute medication orders should carefully verify and strictly follow the"three checks and seven checks"to ensure the accuracy of the time,route,dosage,and other aspects of medication administration.Encourage medical institutions to use information technology to intelligently review and manage the entire process of clinical medication

Establishment of the company

Xi'an Meishang Biotechnology Co., Ltd. (hereinafter referred to as "the Company") was founded on March 30, 2017, and is located in West Area, No. 2, Compound 131, Fengcheng 6th Road, Xi'an Economic and Technological Development Zone. The company has a total laboratory area of 1076 square meters under the Xi'an Maishang Medical Laboratory. It is to create a third-party independent medical laboratory in accordance with international standards. With PCR laboratory certification, clinical cell Molecular genetics professional laboratory certification. On November 7, 2019, it obtained the qualification of "medical laboratory". On July 12, 2020, it was approved as a Nucleic acid test laboratory in Shaanxi Province, and in December of the same year, it was approved as an isolation point Nucleic acid test institution.

Geneva Gold Award Certificate

Silver Award at the 2016 Geneva International Invention Exhibition-Based on Artificial Intelligence Fetal Monitoring System

Special Special Award

US Patent

Special Gold Award at the Geneva International Invention Exhibition

Co construction of Gaoling shelter

On March 2, 2022, a mobile PCR shelter laboratory was unloaded and hoisted. The 17.5m long, 2.98m wide and 2.98m high shelter laboratory was successfully installed in the hospital of Gaoling District Center for Disease Control and Prevention in Xi'an City. The scheme of "mobile shelter laboratory" passed the design review, and was highly recognized and praised by the district government, the disease control centers and hospital experts, And acknowledge the excellent work style and hard work of the project team. Focusing on mobile testing capabilities, we will strengthen the construction of public testing laboratories, urban testing bases, and third-party laboratories. Try not to occupy the daily medical resources in the deployment of experimental personnel. The detection capability of medical institutions mainly guarantees the daily diagnosis and treatment of diseases. Each city (district), according to the population size, will accelerate the upgrading of the Fangcang hospital into a sub (quasi) designated hospital, and comprehensively prepare for the admission of critically ill patients.

Collaborating with Dipu

In November 2021, our company established a long-term and comprehensive strategic partnership with Zhejiang Dipu Diagnosis Technology Co., Ltd. Dipu Diagnosis empowers our partners through standardized systems, improved policies, and continuous training, achieving strong cooperation and complementary advantages. Maishang Biological Laboratory, together with its partners, relies on innovative product technology and strong solution capabilities to continuously meet new customer needs, explore new opportunities, and grow together with our partners.

Carbon dioxide,sulfur dioxide,and biochemical elimination solution and their preparation method

Harmful gas eliminating agent and its preparation method

A natural plant lipid-lowering composition and its preparation method

Prof.Kwok-yin Wong(Intelligent anticancer drug development and testing system)

黄国贤教授，香港大学化学学士、博士、英国皇家化学会会士。

Prof.Xiaoming Tao(Intelligent monitoring system for maternal and fetal safety during pregnancy)

陶教授，华东纺织学院纺织工程学士、澳大利亚新南威尔士大学纺织物理学博士。

Dr. Qiaozhu Chen, Guangzhou Women and Children Medical Center (妊娠期母胎安全智能监护系统)

陈乔珠主任医师，现任合作单位广州市妇女儿童医疗中心产科主任, 该中心是全国最大的一批妇儿专科医院，拥有广泛的患者来源以及完善的电子病历系统，可保证医疗数据的多样性以及可靠性。

Prof. El Fakhri(Intelligent Brain Health Detection and Monitoring Integrated System)

The collaborator Dr. El Fakhri is the Nathaniel & Diana Alpert Professor of Radiology at Harvard Medical School. He is Co-Director of the Division of Nuclear Medicine and Molecular Imaging and founding Director of the Gordon Center for Medical Imaging (GCMI) at MGH. Dr El Fakhri is a recognized expert in SPECT, PET-CT, and PET-MR.

The Ministry of Health and six other departments jointly issued the "Guidelines for Centralized Procurement of High Value Medical Consumables (Trial)"

The "Plan and Implementation Plan for Deepening the Reform of the Medical and Health System during the 12th Five Year Plan" (Guo Fa [2012] No. 11) clearly requires "actively promoting the centralized procurement of high-value medical consumables and medical devices".